Early Optic Nerve Head Glial Proliferation and Jak-Stat Pathway Activation in Chronic Experimental Glaucoma

Diana C. Lozano, Tiffany E. Choe, William O. Cepurna, John C. Morrison, and Elaine C. Johnson

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States

Correspondence: Diana C. Lozano, Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwiliger Boulevard, Portland, OR 97239-4197, USA; lozano@ohsu.edu.

Submitted: September 11, 2018
Accepted: January 25, 2019
Citation: Lozano DC, Choe TE, Cepurna WO, Morrison JC, Johnson EC. Early optic nerve head glial proliferation and Jak-Stat pathway activation in chronic experimental glaucoma. Invest Ophthalmol Vis Sci. 2019;60:921–932. https://doi.org/10.1167/iovs.18-25700

Purpose. We previously reported increased expression of cell proliferation and Jak-Stat pathway–related genes in chronic experimental glaucoma model optic nerve heads (ONHs) with early, mild injury. Here, we confirm these observations by localizing, identifying, and quantifying ONH cellular proliferation and Jak-Stat pathway activation in this model.

Methods. Chronic intraocular pressure (IOP) elevation was achieved via outflow pathway sclerosis. After 5 weeks, ONH longitudinal sections were immunolabeled with proliferation and cell-type markers to determine nuclear densities in the anterior (unmyelinated) and transition (partially myelinated) ONH. Nuclear pStat3 labeling was used to detect Jak-Stat pathway activation. Nuclear density differences between control ONH (uninjected) and ONH with either early or advanced injury (determined by optic nerve injury grading) were identified by ANOVA.

Results. Advanced injury ONH had twice the nuclear density (P < 0.0001) of controls and significantly greater astrocyte density in anterior (P = 0.0001) and transition (P = 0.006) ONH regions. An increased optic nerve injury grade positively correlated with increased microglia/macrophage density in anterior and transition ONH (P < 0.0001, both). Oligodendroglial density was unaffected. In glaucoma model ONH, 80% of anterior and 66% of transition region proliferating cells were astrocytes. Nuclear pStat3 labeling significantly increased in early injury anterior ONH, and 95% colocalized with astrocytes.

Conclusions. Astrocytes account for the majority of proliferating cells, contributing to a doubled nuclear density in advanced injury ONH. Jak-Stat pathway activation is apparent in the early injury glaucoma model ONH. These data confirm dramatic astrocyte cell proliferation and early Jak-Stat pathway activation in ONH injured by elevated IOP.

Keywords: glaucoma, animal models, optic nerve, cell proliferation

Elevated intraocular pressure (IOP) is a well-documented glaucoma risk factor.1,2 Several lines of evidence point to the lamina cribrosa of the optic nerve head (ONH) as the initial site of axonal injury in this disease.3–5 Clinically, glaucoma is characterized by optic disc cupping, neuroretinal rim thinning, and progressive visual field loss. Glaucomeous human eyes demonstrate optic nerve axon and retinal ganglion cell loss accompanied by ONH remodeling and glial scarring.4 Many of these pathophysiological changes are replicated in animal models of glaucoma in which IOP is either experimentally or genetically elevated.4,6–9 Within the normal ONH, astrocytes are arranged into columns. Their processes are oriented perpendicular to retinal ganglion cell axons, separating them into bundles. Astrocytes are the most abundant glial cell type in the ONH, along with microglia. In the posterior ONH, oligodendroglia are increasingly prevalent as axons become myelinated. Both in human glaucoma and in animal glaucoma models with elevated IOP, astrocytes lose their typical arrangement and, along with microglia, alter their morphologies.10–17

In addition to these morphologic changes, our previous studies have shown an upregulation of many cell proliferation–associated genes in glaucoma model ONHs.18,19 To more fully understand the details of this observation, we previously quantified glaucoma model ONH DNA content and found that this increased between 117% (early injury) and 184% (advanced injury) compared to controls.18,19 Furthermore, we showed by three-dimensional reconstructions that the mean ONH volume increased by 40% in early injury glaucoma model nerves.20 These studies provide support for increased cellularity within the glaucomatous ONH but have yet to document cell proliferation or determine which ONH cells are involved in this process.

In addition to these proliferation findings, we found that minimally injured ONHs showed an upregulation of several interleukin-6 type cytokines (Il6, Lif, Clcfl) and Sox3, the feedback inhibitor of Stat3’s phosphorylation (pStat3), suggesting an early activation of the Janus kinase and signal transducer and activator of transcription (Jak-Stat) pathway.18,19 Jak-Stat pathway activation has been shown to regulate glial cell proliferation, as well as astrocytic differentiation, and this pathway may play an important role in the glial responses we have observed in pressure-induced injury.17,18,21–25

The purpose of this study is to answer hypotheses generated by our previous microarray work and identify, in chronic glaucoma model ONHs with early and advanced injury, the presence of proliferating (mitotic) cells and Jak-Stat pathway activation and determine which cells are involved.
Animals were kept in constant dim light for the experimental period. IOP was measured with a rebound tonometer (TonoLab; Colonial Medical Supply, Franklin, NH, USA) in unanesthetized rats as previously described. TonoLab readings. Mean IOP was then determined as the area under the curve of IOP (less the control fellow eye value) for each time point was calculated as the mean of 10 individual IOP acquisitions prior to episcleral vein injection and at least three times a week for the duration of the experiment (5 weeks). IOP was a glial scar.

ONH Immunohistochemistry

Globes, including the ONH, from the above animals were processed for ONH cell identification and quantitation. Globes were randomized into batches (each batch contained control and experimental globes), embedded in paraffin, and longitudinally sectioned vertically, with two sections per slide and 10 to 15 slides per globe. Slides were assigned into immunohistochemistry assay groups to include controls and globes with the full range of nerve injuries in each assay. Sections were immunolabeled with Ki67 or pStat3 and a cell type–specific antibody (Sox2, Iba1, etc.). All slides were labeled with DAPI (4',6-diamidino-2-phenylindole). For the comparisons between anterior and transition regions, slides were selected that contained both, as illustrated in Figure 1. Not every eye was included in every analysis due to the limited number of sections per ONH and availability of appropriate sections for regional comparisons. The sample size for each analysis is provided in each table and figure.

Within each immunohistochemistry assay group, sections were deparaffinized, rehydrated in PBS, and blocked in either 5% goat (Vector Laboratories, Burlingame, CA, USA), horse (Vector Laboratories) or SEA BLOCK blocking buffer (Thermo-Fischer Scientific, Waltham, MA, USA) in PBS, and incubated overnight at 4°C with primary antibodies (Supplementary Table S2). For cell-type markers, primary antibodies used were goat anti-Sox2 (0.3 µg/mL; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for astrocyte nuclei; rabbit anti-Pax2 (0.5 µg/mL; Invitrogen, Carlsbad, CA, USA) for astrocyte nuclei; anti-rabbit glial fibrillary acidic protein (anti-GFAP) (0.5 µg/mL;
DAKO, Carpinteria, CA, USA) for astrocytes; rabbit anti-Iba1 (anti-Aif1, 0.1 μg/mL, Wako Pure Chemical Industries Ltd., Richmond, VA, USA) for microglia/macrophage cells; and rabbit anti-Olig2 (1 μg/mL; Novus Biologicals, Littleton, CO, USA) for oligodendroglia nuclei. Also, mouse anti-Ki67 (usually 0.1 μg/mL, 2 μg/mL for colabeling with Iba1 only; DAKO) was used to identify mitotic nuclei and mouse anti-pStat3 (Tyr705, 1:100; Cell Signaling, Danvers, MA, USA) was used to detect activation of the Jak-Stat pathway.

As has been published previously, these specific primary antibodies were used for antigen immunolocalization in eye or central nervous system tissues as noted in Supplementary Table S2. Additional labeling was performed using the avidin-biotin technique with 3,3'-diaminobenzidine (DAB) chromogen with each primary antibody at the same concentrations as noted in Supplementary Table S2. We provide supplementary images of the cornea (Supplementary Fig. S1) and retina (Supplementary Fig. S2), using DAB to illustrate the specific and expected labeling with these antibodies elsewhere in the eye.

For triple labeling, DAPI and the primary antibody Ki67 (anti-Aif1, 0.1 μg/mL; Wako Pure Chemical Industries Ltd., Richmond, VA, USA) for astrocytes; rabbit anti-Iba1 (anti-Aif1, 0.1 μg/mL, Wako Pure Chemical Industries Ltd., Richmond, VA, USA) for microglia/macrophage cells; and rabbit anti-Olig2 (1 μg/mL; Novus Biologicals, Littleton, CO, USA) for oligodendroglia nuclei. Also, mouse anti-Ki67 (usually 0.1 μg/mL, 2 μg/mL for colabeling with Iba1 only; DAKO) was used to identify mitotic nuclei and mouse anti-pStat3 (Tyr705, 1:100; Cell Signaling, Danvers, MA, USA) was used to detect activation of the Jak-Stat pathway.

Lastly, to determine the specificity of Sox2 as an ONH astrocyte marker with labeling by each cell type antibody. This was accomplished by manually cropping the image to include only the desired ONH region. Image contrast for each color channel was independently and automatically adjusted by removing background noise, correcting for uneven background illumination, and improving image contrast. Each color channel was then thresholded at a standardized level. Given that the camera exposure settings during image acquisition were uniform, a standardized threshold level could be set for each tested primary antibody. In the event that the program yielded too many false positives (e.g., identification of nonnuclear structures), the user could manually adjust the threshold level until all appropriate nuclei were identified.

For nonnuclear antibodies (Iba1 and GFAP), cells were counted when DAPI nuclei were completely surrounded by the label. GFAP+ cells were manually counted because of the complex network of astrocyte labeling within the ONH.

For a subset of ONHs, nuclear densities calculated by the Matlab program were validated by comparing these semi-automated nuclear counts with manual counts performed by a second, independent observer (using Adobe Photoshop CS6 tools; Adobe Systems, San Jose, CA, USA). For this validation study, we focused on comparing anterior ONH nuclear densities done by both methods. An exception was made for Olig2, where nuclear densities in transition ONH were analyzed. There was excellent agreement (P ≥ 0.9) between calculated nuclear densities provided by the two approaches for all primary antibodies (Supplementary Table S5).

**Statistical Analysis**

One-way ANOVA, followed by Dunnett’s multiple comparison test, was used to identify differences in IOP or nerve injury grades between controls and early injury or advanced injury groups.

Nuclear counts were transformed to nuclear densities by dividing the total number of nuclei by the evaluated ONH area. When more than one section per eye was processed, nuclear densities from all sections for a given ONH and region were averaged. Due to the low number of Ki67-labeled nuclei in a given section, proliferating cell nuclear density was calculated by summing the total nuclei divided by the summed area. Where necessary, data were transformed to avoid violating the assumptions of ANOVA.24-35 (However, the raw mean and standard error nuclear densities are reported in Table 2.) One-way ANOVA followed by Dunnett’s multiple comparison test was used to identify differences between controls and either early injury or advanced injury groups. Nerves included in the ONH regional analysis (comparison between anterior and transition ONH) needed to be long enough to have a transition...
ONH Glial Proliferation and Jak-Stat Activation

RESULTS

Elevated IOP and Optic Nerve Injury in Experimental Glaucoma Eyes

IOP parameters (mean IOP and peak IOP) and optic nerve injury grades for control, early injury, and advanced injury groups are summarized in Table 1 and Supplementary Figure S5. Mean IOP in advanced injury (*P* = 0.0001) and peak IOP in both early injury (*P* < 0.0001) and advanced injury (*P* < 0.0001) groups for the 5 weeks following hypertonic saline injection were significantly higher than controls, and duration of IOP elevation in the early injury group was less than in the advanced group. Similarly, nerve injury, as determined by optic nerve injury grade, was significantly greater than controls for both glaucoma model groups (*P* < 0.0001 for both). Additionally, more nerve injury was seen in advanced injury than in early injury (*P* < 0.0001).

In our previous microarray examination of ONH gene expression, we observed two dominant responses in ONH with early injury (less than 15% optic nerve degeneration), the upregulation of genes associated with cell proliferation and those associated with Jak-Stat signaling pathway.18,19 We will first present evidence of cell proliferation in the glaucoma model ONH. Then we will use cell specific markers to quantify total ONH nuclei. Glaucoma model ONHs with advanced injury had a twofold increase in nuclear densities in both the anterior (P < 0.0001) and transition (P < 0.0001) ONH relative to the control group (Fig. 2). Supplementary Figure S6 further illustrates increased cellularity in ONHs with advanced injury. There were no significant differences in DAPI densities between anterior and transition regions within groups (Supplementary Table 4). Regional comparisons presented in this and the following Results paragraphs are based on analysis of data presented in Supplementary Table 4.
Cell Proliferation in Glaucoma Model ONH

To determine if the increased cellularity was, at least in part, due to cell proliferation, we immunostained ONH sections for the mitotic marker Ki67 (Fig. 3). Glaucoma ONHs with early injury (P = 0.0006) and advanced injury (P = 0.001) had significantly more proliferating nuclei than controls (Fig. 3; Table 2), with the highest values in ONHs with early injury. Note that the y-values shown in Figure 3 are a tenth of values plotted in other result figures, further indicating that a small proportion of nuclei are proliferating. Within groups, there were no significant differences between anterior and transition Ki67⁺ nuclear densities (Supplementary Tables S4).

Astrocytic Proliferation in Glaucoma Model ONH

Next, we determined which ONH cells were proliferating in glaucomatous injury. Because astrocytes are the most common cells of the ONH, we first quantified astrocytes using three specific markers, GFAP, Sox2, and Pax2. GFAP is the most commonly used astrocyte marker. However, GFAP is less than satisfactory for quantitative studies in the ONH because it labels the cytoskeleton (rather than nuclei) and because of the complex intertwining of astrocyte processes in the ONH (see Supplementary Fig. S3). Because of this, two additional nuclear markers, Sox2 and Pax2, which produced a more discrete nuclear label, were used. Sox2 is associated with the maintenance of neural stem cells in adult neurogenic areas, which in the anterior ONH could only be astrocytes. Recently, Sox2 mRNA was identified as highly specific to astrocytes in the central nervous system. Sox2 counts agreed best with our counts of GFAP-labeled cells in the anterior region of early injury ONH (4875 ± 376 and 4260 ± 469 cells/mm², respectively, N > 8). Furthermore, we found that that between 81% (anterior ONH) and 93% (transition ONH) of Sox2⁺ nuclei were completely surrounded by GFAP-positive processes. Also, as observed in the mouse ONH, we found Sox2 labeled about 15% more nuclei than Pax2 in the anterior ONH (see Supplementary Fig. S3). Therefore, we used Sox2 to quantify ONH astrocytes.

Advanced injury ONH had more Sox2⁺ nuclei in the anterior (P = 0.0001) and transition (P = 0.0006) regions than controls (Table 2). In regional comparisons within groups (Supplementary Table S4), there were approximately twice as many astrocytes (Sox2⁺) in the anterior compared to the transition region of all groups (P-values: controls = 0.05, early injury = 0.04, and advanced injury < 0.0001; Figs. 4A and 4B). Importantly, when colabeling of nuclei with Sox2 and Ki67 was examined in glaucoma model ONHs, we found that 80% (anterior) and 66% (transition) of mitotic cells labeled as astrocytes (Figs. 4C and 4D).

Microglia/Macrophage Density and Proliferation Rates in Glaucoma Model ONH

For ONH microglia, we used antibodies to Iba1, which also labels macrophages, such as tissue-resident macrophages. To avoid changes in cellular morphology (in response to injury) leading to an overcount of Iba1⁺ cells, we only counted DAPI⁺ nuclei that were contiguous with the surrounding Iba1 label (Fig. 5). In general, we found that during active degeneration, the density of Iba1-labeled cells increased by more than fivefold in both ONH regions. Additionally, while Iba1-labeled cells were always most prevalent in the transition region, the proportion of mitotic Iba1 cells and the relative increase in Iba1 cell density was greatest in the anterior ONH.

More specifically, ONHs with advanced injury had more microglia/macrophages in the anterior ONH (P = 0.01) than controls. Additionally, the transition ONH with early injury (P = 0.0001) and advanced injury (P = 0.0001) had significantly more microglia/macrophages than their respective controls (Table 2). Also, when compared to ONHs with early injury, the advanced injury group had significantly more Iba1⁺...
labeled cells in both ONH locations ($P = 0.0006$ for anterior ONH and $P < 0.0001$ for transition ONH). In both regions, we found Iba1$^+$ cell densities to be positively correlated with optic nerve injury grade (anterior: $r^2 = 0.65, P < 0.0001$, and transition: $r^2 = 0.68, P < 0.0001$). For regional comparisons within groups (Supplementary Table S4), the glaucoma model ONHs had more Iba1$^+$ cells in the transition region than the anterior ONH ($P$ values: early injury $= 0.03$; advanced injury $= 0.02$).

When we examined colabeling of glial model ONH with mitotic cell marker Ki67 and Iba1, we found approximately 14% (anterior) and 4% (transition) of Ki67$^+$ cells were colabeled as microglia/macrophage (Figs. 5C and 5D). Although there was a dramatic increase in Iba1$^+$ cells in the injured ONH, these cells were still the minority of proliferating cells in glaucoma model ONH.

**Oligodendroglial Density in the Transition ONH and Lack of Proliferation in Glaucoma Model ONHs**

The Olig2 antibody was used to identify oligodendroglial nuclei (Fig. 6). Olig2 encodes a basic-helix-loop-helix protein that regulates the development of oligodendrocytes in vertebrates. 40–45 We found nearly all oligodendroglia in the transition ONH region, where densities did not differ significantly between controls and either experimental group ($P$ values: early injury $= 0.08$ and advanced injury $= 0.39$). We found fewer than five Olig2$^+$ nuclei in the anterior ONH in three samples. These tended to be closer to the transition ONH, likely indicating that these eyes were sectioned at a slightly oblique angle. More importantly, we found no Olig2 and Ki67 colabeling, indicating that there was no detectable proliferation of oligodendroglia in the ONH.

**Figure 4.** Astrocytes are the most abundant proliferating glia in glaucoma model ONH. (A) Image of the anterior ONH immunolabeled with astrocyte nuclear marker, Sox2. White arrowheads point to two of the astrocyte nuclei (identified by colocalization of Sox2 in green with DAPI in blue). Scale bar: 10 μm. (B) Mean (±SEM) Sox2$^+$ nuclear densities in the anterior (black bars) and transition (gray bars) regions in controls ($N_{\text{Anterior}} = 17$; $N_{\text{Transition}} = 9$), early injury ($N_{\text{Anterior}} = 19$; $N_{\text{Transition}} = 16$), and advanced injury ($N_{\text{Anterior}} = 11$; $N_{\text{Transition}} = 10$) ONHs. There were significantly more Sox2$^+$ nuclei in the anterior ($P = 0.0001$) and transition ($P = 0.0006$) ONH of the advanced injury than controls (red asterisks; Table 2). There were also nearly twice as many astrocytes in the anterior compared to the transition ONH ($P$ values: controls $= 0.03$, early injury $= 0.04$, and advanced injury $< 0.0001$; Supplementary Table S4). (C) Image of the anterior ONH immunolabeled with Sox2 and Ki67 antibodies. White arrowheads point to two of the proliferating astrocytes as demonstrated by Sox2 (green) and Ki67 (red) nuclear colocalization. Scale bar: 10 μm. (D) In glaucoma model ONH, between 80% (anterior region) and 66% (transition region) of proliferating nuclei were astrocytes (colabeled with Sox2 and Ki67). There was negligible Ki67 labeling in control ONH.

**Figure 5.** Microglia/macrophage density and proliferation in glaucoma model ONH. (A) Image of the anterior ONH immunolabeled for Iba1. White arrowheads point to two microglia/macrophages, identified by DAPI (blue) nucleus surrounded by Iba1 (red) labeling. Scale bar: 10 μm. (B) Mean (±SEM) Iba1$^+$ cell densities in the anterior (black bars) and transition (gray bars) regions in controls ($N_{\text{Anterior}} = 10$; $N_{\text{Transition}} = 7$) ONHs (see Table 2). Significantly more Iba1$^+$ cells were found in the transition ONH with early injury ($P = 0.0001$) and advanced injury ($P = 0.0001$), as well as in the anterior ONH with advanced injury ($P = 0.01$), compared to respective controls (red asterisks). Also, the transition ONH in both glaucoma model ONH groups had more Iba1$^+$ cells than the anterior ONH ($P$ values: early injury $= 0.03$, advanced injury $= 0.02$; see Supplementary Table S4). (C) Image of the anterior ONH immunolabeled for Iba1 and Ki67. White arrowheads point to two proliferating microglia/macrophages (DAPI in blue, Iba1 in red, and Ki67 in green). Scale bar: 10 μm. (D) Density of Ki67$^+$ nuclei that labeled with Iba1$^+$ in the anterior and transition ONH. No more than 15% of Ki67$^+$ nuclei were Iba1$^+$.
Proportional Contribution of Astrocytes, Microglia/Macrophage, and Oligodendroglia to ONH Cellularity in Glaucoma Model ONHs

Figure 7 summarizes the proportional contribution of each cell type to the total number of ONH nuclei by injury group. In general, the proportion of astrocytes (Sox2⁺ nuclei) decreased slightly in experimental glaucoma ONH, while the proportional contribution of microglia/macrophages (Iba1⁺ nuclei) increased. In the transition region, the proportion of oligodendroglia progressively decreased with increasing injury. Additionally, an increasing proportion of nuclei did not label with glial-specific antibodies. These would include non-glial cells, such as fibroblasts, endothelial cells, and pericytes that contribute to the total population of ONH nuclei, as well as any glial cells that fail to express the selected markers.

Jak-Stat Pathway Activation, as Indicated by pSTAT3 Labeling, Primarily Colocalizes With Astrocyte Markers While Colabeling With Microglia/Macrophages is Negligible

In our previous microarray studies, axonal injury in early chronic glaucoma was associated with an upregulation of genes involved with the Jak-Stat pathway. Activation of this pathway can occur when an Il6-type cytokine binds to transmembrane α and gp130 receptors, which then phosphorylates Jak2. Jak2 in turn phosphorylates Stat3 (pStat3). pStat3 homodimers translocate into the nucleus, activating transcription and regulating multiple downstream cell pathways, including proliferation. Here we utilized the pStat3 antibody to localize activation of the Jak-Stat pathway (Fig. 8). Stat3 phosphorylation at this site is associated with canonical Stat3 signaling and astrocyte reactivity. Figure 8 shows that, when compared to their respective controls (Table 2), glaucoma model ONHs had significantly more pStat3⁺ nuclei in both the anterior (P values: early injury = 0.009 and advanced injury = 0.03) and transition ONH (P values: early injury = 0.03 and advanced injury = 0.01). Also, in ONHs with early injury, there were nearly six times more pStat3⁺ nuclei in the anterior compared to the transition region (P = 0.03).

Secondly, we determined if this activation colocalized with astrocytes (Sox2) and/or microglia/macrophages (Iba1). We found pStat3⁺ nuclei almost exclusively colabeled with astrocytes. For example, in the anterior ONH with early injury, about 95% pStat3⁺ nuclei colabeled with Sox2⁺ and only 1% of pStat3⁺ nuclei colabeled with Iba1⁺ nuclei.

DISCUSSION

This study confirms two hypotheses we proposed based on our previous analysis of gene expression changes in glaucoma model ONHs. These are that there is evidence of (1) cell proliferation and (2) Il6-type cytokine signaling via the Jak-Stat signaling pathway in ONHs with early injury. Additionally, we demonstrate that, while both astrocytes and microglia/macroph-
phages proliferate in glaucoma model ONHs, the proliferation of astrocytes predominates.

Increases in cell density are not simply due to the loss of axons in these studies. In a previous study of axon counts versus injury grade in this model, we observed that only 15% of axons were injured in nerves with early injury. Even in nerves with advanced injury, approximately 40% of axons were morphologically normal while axonal debris was in the initial stages of clearance. Importantly, three-dimensional reconstructions of early injury ONH from our model demonstrate that the volume of the ONH increases dramatically. This increase is highly correlated with injury grade and results in an approximate doubling of the volume in ONHs with early injury (grade = 3) compared to controls. Note that the data presented in our current study are based on two-dimensional cell density measurements and, therefore, will actually underestimate the increased cellularity in the expanded volume of early glaucoma ONH.

Significant increases in the number of proliferating ONH cells, the majority of which were identified as astrocytes, were seen in the anterior region in both glaucoma model ONH injury groups. The nuclear Ki67 protein has been shown to be expressed for approximately 24 hours and during all phases of the cell division cycle, including in glial cells. While the overall average percentage of cells that were proliferating at the time of tissue collection was only 2%, from the above it is reasonable to use this as an estimate of the daily rate of proliferation during the entire experimental period (35 days). This rate, applied to the density of DAPI+ nuclei in control ONH (calculated mean advanced injury DAPI density = mean control DAPI density × 1.0235) yields an approximate calculated final density of 13,000 to 14,000 nuclei/mm² and could account for much of the increase in cell density observed in ONHs with advanced injury (Table 2). These increases would also include proliferating microvascular cells, fibroblasts, or other cells that do not label with the cell-type markers that we utilized, as suggested by Figure 7. Another is the proliferation of NG2 (Cspg4+) glial cells, which are only present in the transition region of the rat and have previously been reported to contribute to an increase in the number of oligodendrocytes in myelinated DBA/2J optic nerves with extensive axonal loss.

While ischemia/reperfusion brain injury has been reported to induce astrocyte proliferation, in our microarray study quantifying ONH gene expression changes in nerves with pressures and injury similar to that of the current study, we found that expression of Hif1 and Epo (two hypoxia-related markers) were not significantly different from controls in either early or advanced injury. This, along with optical coherence tomography angiography evidence that retinal and ONH blood flow are not compromised until IOP is well above

![Figure 8](https://www.arvojournals.org)

**Figure 8.** Predominant localization of Jak-Stat activation with astrocytes. Images of the anterior ONH region that were immunolabeled for (A) pStat3 alone (red), (B) pStat3 (red) and Sox2 (green), or (C) the transition ONH immunolabeled for pStat3 (red) and Iba1 (green). Scale bar: 10 μm. In (B), white arrows point out several Sox2+ nuclei colabeled with pStat3+, while other Sox2+ nuclei (white arrowheads) lack pStat3 labeling. In (C), a different ONH section imaged in the transition region, and only one Iba1+ cell (white arrow) colabeled with pStat3. Mean densities of ONH nuclei colabeling by group with (D) pStat3+, (E) pStat3+, and Sox2+ and (F) pStat3+ and Iba1+ anterior (black bars) and transition (gray bars) ONH regions (mean ± SEM; sample size for controls: N_Anterior = 16 and N_Transition = 7; early injury: N_Anterior = 19 and N_Transition = 14; advanced injury N_Anterior = 9 and N_Transition = 9). Red asterisks indicate a significant difference (P < 0.05) from the respective controls.
60 mm Hg, suggests that the astrocyte proliferation observed here is unlikely to be simply a result of ischemia because peak IOPs do not exceed 60 mm Hg during the experimental time period (Supplementary Fig. S5). As anticipated, we found that Iba1-labeled cells (microglia or macrophages) increased in density in injured ONH. Previously, we reported that these increases were correlated with mean IOP exposure, so the proportional relationship to nerve injury reported here was not surprising. However, it is important to note that proliferating Iba1-labeled cells constituted a minority of the mitotic cells in both the anterior and transition ONH regions. In general, in the current study, the Iba1 cell density did not significantly increase until axonal degeneration was advanced, indicating that microglia/macrophage densities are greatest when there is extensive axonal degeneration. Proliferation of these cells is a characteristic response to neural injury in the brain, retina, and optic nerve, and microglial/macrophage proliferative responses have been studied in other glaucoma models in addition to ours. Using the laser photocoagulation model, Ebneter et al. found activation of Iba1- and Ed1 (Cd68)-labeled cells in the retina. ONH, optic nerve, and optic tract, as evidenced by an increase in the labeled area that was correlated with the degree of axonal injury. Bosco et al. demonstrated that early gliosis in DBA/2J mouse optic disks, as detected by confocal scanning laser ophthalmoscopy of CX3CR1+/GFP-labeled cells (microglia or macrophage), was correlated with the degree of optic nerve axonal degeneration. Lastly, it is important to point out that the increase in cell density reported here cannot be attributed primarily to monocytes, since cells labeled with the dual microglial/macrophage marker Iba1 remained a minor component of the ONH, particularly in the anterior region.

While alterations in astrocyte morphology have been documented in glaucoma model ONHs with early injury, simultaneous increases in astrocyte density and proliferation in the ONH have not been carefully documented. We show here that astrocytes constitute the most abundant glial cell type in both the anterior and transition regions of the ONH. In our glaucoma model ONHs, during a time of active axon degeneration, astrocytes more than doubled in density in the anterior region. Additionally, astrocytes accounted for approximately 80% of mitotic glia in the anterior (unmyelinated) ONH and about 65% in the transition region.

When there is destruction of neural tissue, such as in spinal cord injuries or cortical stab wounds, up to 50% of affected astrocytes may divide within a few days and are thought to form a barrier between the lesion and surrounding tissue. In some other types of neural injury, proliferation of microglia or oligodendroglia predominate whereas astrocyte proliferation is less, including in the ONH following optic nerve transection. The robust astrocyte proliferative response observed here by elevated IOP alone may be a unique aspect of early glaucomatous damage in the ONH. The predominance of these early responses in the anterior region, which is the site of the glial lamina and analogous to the primate lamina cribrosa, is consistent with the widely recognized observation that, in glaucoma, the lamina cribrosa is the primary site of injury.

The overall impact of astrocyte proliferation on axon integrity in this glaucoma model is likely twofold. First, while undergoing cell division, astrocytes change in morphology and their specific gene and protein expressions are altered, all of which may compromise their ability to provide functional support to axons passing through the ONH. In the ONH, as elsewhere in the nervous system, astrocytic functions include regulation of water and ion fluxes, support for action potential propagation, the provision of metabolic precursors via vascular interactions and glycogen storage, the supply of neurotrophic factors and antioxidants, the provision of communication and diffusion via gap junctions, the removal of cellular debris, and the generation of extracellular matrix. Unmyelinated axons of the anterior ONH are particularly vulnerable to this decreased support due to their high metabolic demands. Second, cell proliferation itself is an energy-consuming process that can double astrocyte glucose uptake. Therefore, cell proliferation in the injured ONH is likely to place an additional metabolic stress on injured and remaining ONH axons.

In our microarray study, we identified upregulation of cell proliferation genes as well as genes associated with interleukin 6-type cytokines and the Jak-Stat signaling pathway. Here we demonstrate that early in glaucomatous injury, the transcription factor, Stat3, is activated by phosphorylation in the ONH and that this occurs primarily in astrocytes. This labeling is most dramatic in conjunction with significant Ki67 labeling in these cells in the anterior region of the ONH, where the greatest increase in astrocyte density occurs. This suggests that Stat3 phosphorylation may signal astrocyte proliferation in response to elevated IOP injury. A key role for this pathway in astrocyte proliferation has been described in the spinal cord and brain injury.

Stat3 has been identified as necessary and sufficient for astrocyte differentiation and is a central regulator of astrocyte reactivity and proliferation. Pharmacologic inhibition of ONH Stat3 following ischemic injury has been reported to increase axon survival in the optic nerve and retina, as well as ganglion cell survival. In other neural tissues, Stat3 deletion or inhibition has been reported to reduce gliosis and both reduce and increase neural injury. Therefore, while Stat3 phosphorylation may signal astrocytic proliferation in glaucoma model ONH, this has not been conclusively demonstrated, and the overall roles of Stat3 activation and the pathways that it may signal, including cell proliferation, in axonal degeneration warrant further clarification using other models of induced as well as experimental glaucoma.

One of the biggest challenges with any chronic experimental glaucoma model is that it is difficult to separate temporally early from late events. We, and others, have equated minimal focal injury with early injury and more widespread injury with advanced injury. The time course for these protein expression changes must be inferred, because IOP magnitude and duration cannot be precisely controlled. To address this problem, we recently developed a controlled elevation of IOP (CEI) model that produces many of the ONH message changes and axonal injury patterns seen previously in our chronic model. The advantage of this approach is that pressure is elevated to a known level for a specific amount of time, and animals can be studied at any recovery time point following this exposure. In this new model, we showed that there is significant upregulation of various II-6 type cytokines in the ONH during pressure elevation and that this precedes increases in cell proliferation–related genes (e.g., Top2A and Prc1), further supporting early involvement of the Jak-Stat pathway and consistent with the possibility that this drives cell proliferation. Further studies using this model are now underway to understand better the chronologic events leading to glial proliferation in the ONH and determine their relationship to axonal injury.
Acknowledgments

Supported by NIH/NEI Grants R01EY010145-17S1 (DCL), R01EY-010145 (JCM), R01EY016866 (ECJ); and P30 EY010572 (OHU), and by unrestricted departmental funding from Research to Prevent Blindness (New York, NY, USA).

Disclosure: D.C. Lozano, None; T.E. Choe, None; W.O. Cepurna, None; J.C. Morrison, None; E.C. Johnson, None

References

ONH Glial Proliferation and Jak-Stat Activation


77. Quigley HA, Hohman RM, Addicks EM, Massof RW, Green WR. Morphologic changes in the lamina cribrosa correlated
with neural loss in open-angle glaucoma. *Am J Ophthalmo*.
1983;95:675–691.


107. Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. *Invest Ophthalmo Vis Sci*. 2000;41:741–748.


